No Prescription |
 |
 | ||
|
P Glitz Actos |
|
| ||
No Prescription » Prescription Drugs 12 » P Glitz Actos Pioglitazone is an oral diabetes medicine that help control blood sugar levels. Pioglitazone is for people with type 2 diabetes who do not use daily insulin injections. This medication is not for treating type 1 diabetes. Pioglitazone (pye-oh-GLI-ta-zone) is used to treat a certain type of diabetes mellitus (sugar diabetes) called type 2 diabetes. It may be used alone with insulin or with metformin or another type of oral diabetes medicine called a sulfonylurea. Pioglitazone is indicated as an adjunct to diet and exercise as a once-daily combination therapy to improve glycemic control in patients with type 2 diabetes who are already treated with a combination of pioglitazone and a sulfonylurea or whose diabetes is not adequately controlled with a sulfonylurea alone or for those patients who have initially responded to pioglitazone alone and require additional glycemic control. Management of type 2 diabetes should also include nutritional counseling weight reduction as needed and exercise. These efforts are important not only in the primary< treatment of type 2 diabetes but also to maintain the efficacy of drug therapy. Buy P Glitz Actos and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About P Glitz Actos: Product Type: Prescription Drugs 12 P-Carzine (Matulane Generic Procarbazine) P Glitz (Actos Duetact Generic Pioglitazone) Actos Duetact Generic Pioglitazone 45mg Actos Duetact Generic Pioglitazone P Glitz
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
